Results 181 to 190 of about 10,523 (190)

Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review

Expert Review of Clinical Pharmacology, 2020
S U Zuidema, Hendrika J Luijendijk
exaly  

Oral PCSK9 inhibitor is effective and safe

Nature Reviews Cardiology, 2023
openaire   +2 more sources

PCSK9 inhibitor effectively attenuates cardiometabolic impairment in obese-insulin resistant rats

European Journal of Pharmacology, 2020
Siripong Palee, Busarin Arunsak, Wasana Pratchayasakul   +2 more
exaly  

What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?

Cardiovascular Research, 2019
, Peter E Penson, Banach Maciej
exaly  

Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates

Journal of Clinical Lipidology, 2019
Victoria W Reynolds, Leena Choi, Samuel Nwosu   +2 more
exaly  

Cost-effectiveness of PCSK9 Inhibitor Therapy

JAMA, 2016
Vera, Mastey, Bryan M, Johnstone
openaire   +2 more sources

PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid‐lowering effects

Journal of Cellular and Molecular Medicine, 2019
Siripong Palee, Thidarat Jaiwongkam, Sasiwan Kerdphoo   +2 more
exaly  

Periphere arterielle Verschlusskrankheit: Wann ist ein PCSK9-Inhibitor sinnvoll?

Deutsche Medizinische Wochenschrift, 2018
Knut Kröger, Christoph Kalka, Holger Lawall   +2 more
exaly  

[First PCSK9 inhibitor].

MMW Fortschritte der Medizin, 2016
openaire   +1 more source

PCSK9 inhibitors on the way.

Managed care (Langhorne, Pa.), 2015
openaire   +1 more source